|
SEATTLE (AP) -- Biotechnology drug developer Oncothyreon Inc. said Monday that Douglas E. Williams was named to its board.
Williams, 51, currently serves as chief executive of ZymoGenetics Inc. He previously held senior level positions at Seattle Genetics Inc., Immunex Corp. and Amgen Inc. He is also a director of Array BioPharma Inc. and Aerovance Inc. Oncothyreon specializes in the development of therapies to treat cancer. Sentiment : Strong Buy Rating :
 (No ratings) |
 Connecticut |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|